View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 10, 2022

Freeline Therapeutics doses first subject in haemophilia B therapy trial

The study will use an initial 7.7e11vg/kg dose and a short course of prophylactic immune management to normalise FIX levels.

Freeline Therapeutics has dosed the first subject in the Phase I/II B-LIEVE clinical trial of its therapy FLT180a to treat haemophilia B.

FLT180a is a next-generation adeno-associated virus (AAV) gene therapy to treat haemophilia B, a genetic bleeding disorder that is caused by the clotting factor IX protein deficiency.

It uses the adeno-associated virus vector capsid (AAVS3) for providing the function gene of a variant of human factor IX and to restore the formation of normal blood clots.

The study is a dose-confirmation trial of FLT180a, which is produced at a commercial scale.

In this trial, 7.7e11vg/kg of initial dose and a short course of prophylactic immune management will be used to normalise the FIX levels.

Freeline stated that the dose was selected depending on the data obtained from B-AMAZE, as well as many modelling approaches.

The B-LIEVE study is expected to finalise a dose for the planned Phase III pivotal trial, which is designed to consistently normalise FIX levels in haemophilia B patients.

Freeline Therapeutics chief medical officer Pamela Foulds said: “We are optimistic that the combination of a low dose (7.7e11vg/kg) of our high-expression AAVS3 capsid with a short prophylactic immune management regimen can get and keep haemophilia B patients in the normal range of Factor IX expression.

“This is a meaningful step towards realising the potential of FLT180a to provide a functional cure through sustained, normalised FIX activity.”

The preliminary safety and biomarker data from the B-LIEVE trial’s first dose cohort is expected in the first half of this year.

Freeline expects to complete the additional patients dosing in the first cohort or dosing of the second cohort if necessary, by the end of the third quarter of this year.

Furthermore, the company expects to begin the start-up activities for the Phase III trial in the first half of next year.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU